Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

The majority of patients with chronic myeloid leukemia are successfully managed with life-long treatment with tyrosine kinase inhibitors. In patients in chronic phase, other malignancies are among the most common causes of death, raising concerns on the relationship between these deaths and the off-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gugliotta, Gabriele, Castagnetti, Fausto, Breccia, Massimo, Albano, Francesco, Iurlo, Alessandra, Intermesoli, Tamara, Abruzzese, Elisabetta, Levato, Luciano, D’Adda, Mariella, Pregno, Patrizia, Cavazzini, Francesco, Stagno, Fabio, Martino, Bruno, La Barba, Gaetano, Sorà, Federica, Tiribelli, Mario, Bigazzi, Catia, Binotto, Gianni, Bonifacio, Massimiliano, Caracciolo, Clementina, Soverini, Simona, Foà, Robin, Cavo, Michele, Martinelli, Giovanni, Pane, Fabrizio, Saglio, Giuseppe, Baccarani, Michele, Rosti, Gianantonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685244/
https://www.ncbi.nlm.nih.gov/pubmed/28572163
http://dx.doi.org/10.3324/haematol.2017.169532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685244/
https://www.ncbi.nlm.nih.gov/pubmed/28572163
http://dx.doi.org/10.3324/haematol.2017.169532

Ejemplares similares